{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:07:12Z","timestamp":1784110032347,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is common world-wide. Current diagnostics based on testing for circulating levels of prostate specific antigen (PSA) is unspecific, and novel prognostic markers are needed for personalized therapeutic strategies. Pro-neuropeptide Y (pro-NPY) has been reported as a tissue marker for PCa related to poor prognosis. This study explored the prognostic value of circulating pro-NPY in PCa. Plasma samples were obtained from two patient cohorts: (1) men examined due to increased PSA levels in 2003\u20132011 (n\u2009=\u2009796) and (2) patients treated for PCa in 2013\u20132016 (n\u2009=\u200992). Cohort 2 also provided plasma samples collected\u2009~\u20093\u00a0months after therapy. For plasma pro-NPY assessment, a sandwich immunoassay was developed. In cohort 1, 315 patients were diagnosed with PCa at the time for blood sampling, 137 were diagnosed during follow-up, and 344 remained disease-free. Plasma pro-NPY provided independent prognostic information from PSA regarding time to metastasis and PCa death. In cohort 2, high plasma pro-NPY levels were confirmed associated with metastatic disease and poor survival. Plasma pro-NPY levels were normalized after androgen-deprivation therapy, suggesting androgen-regulation. In conclusion, high circulating pro-NPY levels are associated with metastasis and poor outcome in PCa. Prospective validation is needed before suggesting pro-NPY for clinical use. The underlying biology and consequences of pro-NPY overexpression remain to be understood.<\/jats:p>","DOI":"10.1038\/s41598-026-58517-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:47:03Z","timestamp":1782186423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Erik","family":"Djusberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lundholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Thellenberg","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen M.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Brattsand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"3","key":"58517_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"58517_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86(2), 148\u2013163 (2024).","journal-title":"Eur. Urol."},{"issue":"12","key":"58517_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson, J. et al. Results after four years of screening for prostate cancer with PSA and MRI. N. Engl. J. Med. 391(12), 1083\u20131095 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"58517_CR4","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario, U. G. et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw. Open 6(9), e2332900 (2023).","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"58517_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore, N. D. et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 27(2), 192\u2013201 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"58517_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.eururo.2015.10.053","volume":"69","author":"D Iglesias-Gato","year":"2016","unstructured":"Iglesias-Gato, D. et al. The proteome of primary prostate cancer. Eur. Urol. 69(5), 942\u2013952 (2016).","journal-title":"Eur. Urol."},{"issue":"10","key":"58517_CR7","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1021\/pr400547s","volume":"12","author":"K Ueda","year":"2013","unstructured":"Ueda, K. et al. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. J. Proteome Res. 12(10), 4497\u20134506 (2013).","journal-title":"J. Proteome Res."},{"key":"58517_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.euros.2024.06.008","volume":"66","author":"J Maurer","year":"2024","unstructured":"Maurer, J. et al. Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection. Eur. Urol. Open Sci. 66, 12\u201315 (2024).","journal-title":"Eur. Urol. Open Sci."},{"key":"58517_CR9","doi-asserted-by":"crossref","unstructured":"Grouzmann, E. & Brakch, N. NPY processing in neuronal and non-neuronal tissues by proconvertases. The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer 63\u201371. (2005).","DOI":"10.1007\/3-7643-7427-6_3"},{"issue":"4","key":"58517_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.npep.2004.07.002","volume":"38","author":"DR Gehlret","year":"2004","unstructured":"Gehlret, D. R. Introduction to the reviews on neuropeptide Y. Neuropeptides 38(4), 135\u2013140 (2004).","journal-title":"Neuropeptides"},{"key":"58517_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","volume":"55","author":"F Reichmann","year":"2016","unstructured":"Reichmann, F. & Holzer, P. Neuropeptide Y: a stressful review. Neuropeptides 55, 99\u2013109 (2016).","journal-title":"Neuropeptides"},{"issue":"5","key":"58517_CR12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jnr.24589","volume":"98","author":"U Tural","year":"2020","unstructured":"Tural, U. & Iosifescu, D. V. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J. Neurosci. Res. 98(5), 950\u2013963 (2020).","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"58517_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000486225","volume":"45","author":"M Yi","year":"2018","unstructured":"Yi, M. et al. A promising therapeutic target for metabolic diseases: neuropeptide Y receptors in humans. Cell. Physiol. Biochem. 45(1), 88\u2013107 (2018).","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"58517_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2011.03.011","volume":"131","author":"L Zhang","year":"2011","unstructured":"Zhang, L., Bijker, M. S. & Herzog, H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 131(1), 91\u2013113 (2011).","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"58517_CR15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1210\/en.2005-0925","volume":"147","author":"M Ruscica","year":"2006","unstructured":"Ruscica, M. et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 147(3), 1466\u20131473 (2006).","journal-title":"Endocrinology"},{"key":"58517_CR16","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-18-2912","volume":"25","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y. et al. Depression-induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells. Clin. Cancer Res. 25, 2621\u20132632 (2019).","journal-title":"Clin Cancer Res"},{"issue":"1","key":"58517_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/pros.24081","volume":"81","author":"Y Ding","year":"2021","unstructured":"Ding, Y. et al. Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance. Prostate 81(1), 58\u201371 (2021).","journal-title":"Prostate"},{"key":"58517_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.peptides.2013.07.029","volume":"48","author":"PJ Medeiros","year":"2013","unstructured":"Medeiros, P. J. & Jackson, D. N. Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis. Peptides 48, 106\u2013113 (2013).","journal-title":"Peptides"},{"issue":"24","key":"58517_CR19","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1038\/onc.2014.253","volume":"34","author":"M Czarnecka","year":"2015","unstructured":"Czarnecka, M. et al. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance. Oncogene 34(24), 3131\u20133143 (2015).","journal-title":"Oncogene"},{"issue":"1","key":"58517_CR20","doi-asserted-by":"publisher","first-page":"8324","DOI":"10.1038\/s41598-019-43552-5","volume":"9","author":"C Fredolini","year":"2019","unstructured":"Fredolini, C. et al. Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles. Sci. Rep. 9(1), 8324 (2019).","journal-title":"Sci. Rep."},{"issue":"15","key":"58517_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201900008","volume":"19","author":"RS H\u00e4ussler","year":"2019","unstructured":"H\u00e4ussler, R. S. et al. Systematic development of sandwich immunoassays for the plasma secretome. Proteomics 19(15), e1900008 (2019).","journal-title":"Proteomics"},{"issue":"3","key":"58517_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4274\/uob.galenos.2024.2024.3.1","volume":"23","author":"A \u00d6zt\u00fcrk","year":"2024","unstructured":"\u00d6zt\u00fcrk, A. et al. Comparison of prostate specific antigen and neuropeptide y parameters in patients with prostate cancer. Bull Urooncol. 23(3), 78\u201383 (2024).","journal-title":"Bull Urooncol."},{"issue":"1","key":"58517_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1743-7075-9-52","volume":"9","author":"D Sedlackova","year":"2012","unstructured":"Sedlackova, D. et al. Comparison of a high-carbohydrate and high-protein breakfast effect on plasma ghrelin, obestatin, NPY and PYY levels in women with anorexia and bulimia nervosa. Nutr. Metab. (Lond.) 9(1), 52 (2012).","journal-title":"Nutr. Metab. (Lond.)"},{"issue":"8032","key":"58517_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41586-024-07863-6","volume":"634","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. Sympathetic neuropeptide Y protects from obesity by sustaining thermogenic fat. Nature 634(8032), 243\u2013250 (2024).","journal-title":"Nature"},{"issue":"1","key":"58517_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1021\/acs.analchem.9b03505","volume":"92","author":"C Vocat","year":"2020","unstructured":"Vocat, C. et al. Quantification of neuropeptide Y and Four of its metabolites in human plasma by micro-UHPLC-MS\/MS. Anal. Chem. 92(1), 859\u2013866 (2020).","journal-title":"Anal. Chem."},{"issue":"12","key":"58517_CR26","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0026-0495(97)90136-0","volume":"46","author":"B Baranowska","year":"1997","unstructured":"Baranowska, B. et al. galanin, and leptin release in obese women and in women with anorexia nervosa. Metabolism 46(12), 1384\u20131389 (1997).","journal-title":"Metabolism"},{"issue":"3","key":"58517_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/apha.12445","volume":"213","author":"A Farzi","year":"2015","unstructured":"Farzi, A., Reichmann, F. & Holzer, P. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol. (Oxf.) 213(3), 603\u2013627 (2015).","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"7","key":"58517_CR28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1113\/JP285945","volume":"603","author":"VYH van Weperen","year":"2025","unstructured":"van Weperen, V. Y. H. et al. Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of \u03b2-adrenergic receptors. J. Physiol. 603(7), 1911\u20131921 (2025).","journal-title":"J. Physiol."},{"issue":"2","key":"58517_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055207","volume":"8","author":"P Massoner","year":"2013","unstructured":"Massoner, P. et al. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS ONE 8(2), e55207 (2013).","journal-title":"PLoS ONE"},{"issue":"27","key":"58517_CR30","doi-asserted-by":"publisher","first-page":"42071","DOI":"10.18632\/oncotarget.9817","volume":"7","author":"AF Hansen","year":"2016","unstructured":"Hansen, A. F. et al. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer. Oncotarget 7(27), 42071\u201342085 (2016).","journal-title":"Oncotarget"},{"issue":"10","key":"58517_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/apm.12886","volume":"126","author":"G Kristensen","year":"2018","unstructured":"Kristensen, G. et al. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. APMIS 126(10), 804\u2013813 (2018).","journal-title":"APMIS"},{"issue":"4","key":"58517_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.euo.2019.05.001","volume":"2","author":"M Alshalalfa","year":"2019","unstructured":"Alshalalfa, M. et al. Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications. Eur. Urol. Oncol. 2(4), 405\u2013412 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"58517_CR33","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1007\/s00432-022-04540-x","volume":"149","author":"D Sigorski","year":"2023","unstructured":"Sigorski, D. et al. Neuropeptide Y and its receptors in PCa: associations with cancer invasiveness and perineural spread. J. Cancer Res. Clin. Oncol. 149, 5803\u20135822 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"41","key":"58517_CR34","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1038\/onc.2010.301","volume":"29","author":"C Lu","year":"2010","unstructured":"Lu, C. et al. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 29(41), 5630\u20135642 (2010).","journal-title":"Oncogene"},{"issue":"3","key":"58517_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101645","volume":"298","author":"PJ Medeiros","year":"2022","unstructured":"Medeiros, P. J., Pascetta, S. A., Kirsh, S. M., Al-Khazraji, B. K. & Uniacke, J. Expression of hypoxia inducible factor-dependent neuropeptide Y receptors Y1 and Y5 sensitizes hypoxic cells to NPY stimulation. J. Biol. Chem. 298(3), 101645 (2022).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"58517_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29898-x","volume":"13","author":"C Lu","year":"2022","unstructured":"Lu, C. et al. Hypoxia-activated neuropeptide Y\/Y5 receptor\/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma. Nat. Commun. 13(1), 2323 (2022).","journal-title":"Nat. Commun."},{"issue":"1","key":"58517_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10237-z","volume":"44","author":"D Sigorski","year":"2025","unstructured":"Sigorski, D. et al. Neuropeptide Y in cancer-biological functions and potential clinical implications. Cancer Metastasis Rev. 44(1), 21 (2025).","journal-title":"Cancer Metastasis Rev."}],"updated-by":[{"DOI":"10.1038\/s41598-026-61181-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58517-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:25:27Z","timestamp":1784107527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58517-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58517"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58517-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-61181-7","URL":"https:\/\/doi.org\/10.1038\/s41598-026-61181-7","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used ChatGPT (openai.com) to improve language and readability of the text. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19518"}}